It has been nearly fifteen years since the Food and Drug Administration (FDA) approved the first therapeutic cancer vaccine for solid tumors, namely Sipuleucel-T (Provenge®), marking a significant milestone in the treatment of metastatic castration-resistant prostate cancer [...].